Gossamer Bio Announces Promotion of Richard Aranda, MD, to Medical Director


SAN DIEGO – (COMMERCIAL THREAD) –Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the discovery, acquisition, development and commercialization of therapeutics in the pathological areas of immunology, inflammation and oncology, announced Today that, Richard Aranda, MD, previously Senior Vice President and Head of Clinical Development Services, will be promoted to Chief Medical Officer. Dr Aranda joined Gossamer in February 2018 with responsibilities including oversight of clinical pharmacology, translational medicine and pharmacovigilance.

“Dr. Richard Aranda’s clinical development expertise has been vital to Gossamer since its inception, ”said Faheem Hasnain, President, Co-Founder and CEO of Gossamer Bio. “Dr Aranda is an experienced drug developer and clinician, and under his continued strong leadership, I have no doubts that Gossamer is in the best position to be successful.

Prior to joining Gossamer Bio, Dr Aranda was Vice President of Clinical Development at Receptos, Inc. (Celgene Corporation), from 2015 to 2018, where he contributed to the advanced development programs of ozanimod (Zeposia) in sclerosis in plaques and inflammatory diseases. bowel disease (IBD) and RPC4046 in eosinophilic esophagitis. Prior to joining Receptos, from 2011 to 2015, Dr. Aranda was Vice President of Medical Sciences and Inflammation at Novo-Nordisk, Inc., where he played a key role in advancing several biologic product candidates to ‘in phase 1 until proof of concept. studies in rheumatoid arthritis (RA), systemic lupus erythematosus and IBD. Dr Aranda began his career in industry at Bristol Myers Squibb in 2001, where he held positions of increasing scope and responsibility, including as Global Medical Manager for abatacept (Orencia), as well as leader of the early development team for the early stage immunology product. candidates. As Global Medical Lead, Dr Aranda has contributed to the development and approval of Orencia for the treatment of RA and juvenile arthritis and to the exploration of Orencia in other immune-mediated disorders. .

Prior to joining the pharmaceutical industry, Dr Aranda was on the faculty of the Division of Digestive Diseases and West Los Angeles Veterans Affairs, University of California, Los Angeles (UCLA) School of Medicine where he was involved in patient care and immunological research in the laboratory. . Dr. Aranda received his medical training at Harbor-UCLA and his training in clinical research and immunology research as part of UCLA’s Integrated Gastroenterology Training Program. He received his MD from Stanford Medical School and his undergraduate degree from the University of California at Santa Cruz.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the discovery, acquisition, development and commercialization of therapeutics in the pathological areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to improve and extend the lives of patients suffering from these diseases.


About Hector Hedgepeth

Check Also

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for …

Leave a Reply

Your email address will not be published.